Evidence map›Paper›PMID 35460461›Full record

Observational studyJournal of endocrinological investigation2022

Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1-84) treatment.

G Marcucci, G Beccuti, G Carosi, F Cetani, L Cianferotti, A M Colao, C Di Somma, M Duradoni, A Elefante, L Ghizzoni and 13 more

Open access · hybridAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of endocrinological investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Escherichia coli in the production of biopharmaceuticals.Biotechnology and applied biochemistry · 2025
    Review
  4. Review
  5. Article
  6. Review
  7. Parathyroid diseases and metabolic syndrome.Journal of endocrinological investigation · 2023
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 13 institutions in 1 country.

G MarcucciBone Metabolic Diseases Unit, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy.
G BeccutiDepartment of Medical Sciences, Division of Endocrinology, Diabetes and Metabolism, University of Turin, Corso Dogliotti 14, 10126, Turin, Italy.
G CarosiEndocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
F CetaniDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
L CianferottiBone Metabolic Diseases Unit, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy.
A M ColaoDepartment of Clinical Medicine and Surgery, Endocrinology Unit, University Medical School of Naples, Via Sergio Pansini 5, 80131, Naples, Italy.
C Di SommaDepartment of Clinical Medicine and Surgery, Endocrinology Unit, University Medical School of Naples, Via Sergio Pansini 5, 80131, Naples, Italy.
M DuradoniDepartment of Information Engineering, University of Florence, Florence, Italy.
A ElefanteAzienda Ospedaliera Regionale San Carlo, Potenza, Italy.
L GhizzoniDepartment of Medical Sciences, Division of Endocrinology, Diabetes and Metabolism, University of Turin, Corso Dogliotti 14, 10126, Turin, Italy.
M GiustiEndocrinology Unit, Department of Internal Medicine and Medical Specialties (DiMI), University of Genoa, Genoa, Italy.
A G LaniaDepartment of Biomedical Sciences, Humanitas University, 20090, Pieve Emanuele, Italy.
E LavezziEndocrinology, Diabetology and Andrology Unit, Humanitas Clinical and Research Center-IRCCS, 20089, Rozzano, Italy.
B MadeoUnit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-Universitaria Di Modena, Modena, Italy.
G MantovaniEndocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
C MarcocciDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
L MasiAUO-Careggi University Hospital, Florence, Italy.
S ParriBone Metabolic Diseases Unit, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy.
F PigliaruEndocrinology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
A SantonatiDepartment of Endocrinology and Diabetology, Azienda Ospedaliera San Giovanni Addolorata, Rome, Italy.
A SpadaDepartment of Endocrinology and Diabetology, Azienda Ospedaliera San Giovanni Addolorata, Rome, Italy.
L VeraEndocrinology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
M L BrandiFondazione Italiana Di Ricerca Sulle Malattie Dell'osso: F.I.R.M.O, Via San Gallo 123, 50100, Florence, Italy. marialuisa@marialuisabrandi.it.ORCID http://orcid.org/0000-0002-8741-0592
University of Florence · ITAzienda Ospedaliera San Giovanni Addolorata · ITHumanitas University · ITUniversity of Milan · ITUniversity of Pisa · ITUniversity of Turin · ITAzienda Ospedaliera Carlo Poma · ITAzienda Ospedaliero-Universitaria Careggi · ITAzienda Ospedaliero-Universitaria di Modena · ITOspedale Policlinico San Martino · ITSanta Maria Nuova Hospital · ITUniversity of Cagliari · ITUniversity of Genoa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe main purpose of this study was to investigate the effects of 12 months of rhPTH (1-84) (Natpar

methodsIt is a multicenter, observational, retro-prospective, open label study. Eleven Italian Endocrinological centers, members of Hypoparathyroidism Working Group of the Italian Society of Endocrinology (HypoparaNET) were involved. Main outcome measures were serum and urinary calcium and phosphate concentration, calcium-phosphate product, renal function, oral calcium and vitamin D doses, and clinical manifestations.

resultsFourteen adult subjects, affected by chronic hypoparathyroidism, were treated with rhPTH (1-84) for 12 months. At 12 months of rhPTH (1-84) treatment, 61.5% of patients discontinued calcium supplement and 69.2% calcitriol. Mean albumin-adjusted total serum calcium levels quickly normalized after initiation of rhPTH (1-84) treatment compared to baseline (p = 0.009), remaining in the normal range until 12 months. Rare hypo-hypercalcemia episodes were reported. Renal function was maintained normal and no renal complications were reported. Serum and urinary phosphate and urinary calcium were maintained in the normal range. Mean phosphatemia levels linearly decreased from 3 months up to 12 months compared to baseline (p = 0.014). No severe adverse events were described.

conclusionsBiochemical and clinical results confirm the efficacy and safety of rhPTH (1-84) therapy, which represents an important option for hypoparathyroid patients unresponsive to conventional therapy.

Indexed as

CalciumHypoparathyroidismAdultHumansParathyroid HormonePhosphatesProspective StudiesTreatment OutcomeCalciumParathyroid HormonePhosphatesChronic hypoparathyroidismNatpar®rhPTH (1–84)Treatment

Identifiers

PMID35460461
PMCPMC9360119
OpenAlexW4226073001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.